[1] |
XIAO Yi, WU Ming, YAO Gang.
Research progress and future perspectives of tumor organoid
[J]. China Oncology, 2024, 34(8): 763-776.
|
[2] |
LIANG Yingyun, CHEN Jianhua.
Application progress of oncolytic virus combined with immunotherapy in the treatment of malignant tumors
[J]. China Oncology, 2024, 34(7): 686-694.
|
[3] |
CHEN Hongyu, SU Pengyu, LUO Wenzi, PANG Dequan, WANG Feiran.
A study of relationship between cardiac exposure dose-volume and cardiovascular autonomic dysfunction in radiotherapy
[J]. China Oncology, 2024, 34(11): 1036-1044.
|
[4] |
YANG Ziyi, GU Bingxin, XU Xiaoping, SONG Shaoli.
Comparison of 18F-FDG and 68Ga-FAPI PET/CT in the diagnosis of lung metastasis in different malignant tumors
[J]. China Oncology, 2023, 33(9): 829-833.
|
[5] |
Expert Committee on Immunotherapy of Chinese Society of Clinical Oncology , Professional Committee on Cancer Biotherapy of Shanghai Anticancer Association .
Chinese expert consensus on clinical application of recombinant oncolytic adenovirus in the treatment of malignant tumors
[J]. China Oncology, 2023, 33(5): 527-548.
|
[6] |
Society of Onco-Endocrinology of Chinese Anti-Cancer Association.
Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition)
[J]. China Oncology, 2023, 33(10): 954-967.
|
[7] |
CHEN Zhujun, DING Zhimin, MA Xiaolu, WANG Yanchun, HU Haoyun, LU Renquan, GUO Lin.
Analysis of characteristics of infectious pathogens in malignant tumors combined with bloodstream infection and significance of serum glucose detection
[J]. China Oncology, 2023, 33(10): 927-935.
|
[8] |
HU Xichun, HU Zhihuang, WANG Biyun, WANG Jialei, TAO Rong, ZHANG Jian, GUO Weijian, CHEN Jie, LUO Zhiguo, LI Ting, HUANG Mingzhu, QIU Lixin, SANG Youzhou.
COVID-19 and systemic anti-cancer therapy
[J]. China Oncology, 2022, 32(6): 499-511.
|
[9] |
Society of Onco-endocrinology of Chinese Anti-Cancer Association.
Expert consensus on metformin adjuvant therapy in malignant tumor patients with diabetes mellitus type 2 (2022 edition)
[J]. China Oncology, 2022, 32(11): 1121-1132.
|
[10] |
ZHU Junjun, GE Naijian, YANG Yefa.
Current status and prospects of migration of radioactive 125 I seed implanted in malignant tumor
[J]. China Oncology, 2021, 31(4): 257-262.
|
[11] |
ZHAO Yudi, TAN Fang, YAN Zhiling, LI Yingfu, DAI Shuying, ZHOU Ziyun, ZHANG Xinwen, LIU Shuyuan, SHI Li, YAO Yufeng.
Correlation between genetic variants in CD44 gene and cervical cancer and non-small cell lung cancer
[J]. China Oncology, 2019, 29(4): 277-283.
|
[12] |
ZHOU Di, LIU Lingshuang, JIANG Yi, et al.
Single arm and single center clinical research on traditional Chinese medicine in combination with apatinib for the treatment of stage Ⅳ malignant tumor
[J]. China Oncology, 2018, 28(11): 833-839.
|
[13] |
LI Min, XIE Ming.
Advances in research on multiple primary malignant tumors
[J]. China Oncology, 2017, 27(2): 156-160.
|
[14] |
LIU Yue’e, REN Xiaocang, CHEN Xueji, et al.
Dose escalation of lobaplatin combined with fixed docetaxel in second-line chemotherapy with solid tumors
[J]. China Oncology, 2015, 25(3): 211-216.
|